-
1
-
-
0029243810
-
How many women have osteoporosis now?
-
Melton LJ III. How many women have osteoporosis now? J Bone Miner Res 1995;10:175-7.
-
(1995)
J Bone Miner Res
, vol.10
, pp. 175-177
-
-
Melton L.J. III1
-
2
-
-
0028060362
-
The diagnosis of osteoporosis
-
Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-41.
-
(1994)
J Bone Miner Res
, vol.9
, pp. 1137-1141
-
-
Kanis, J.A.1
Melton L.J. III2
Christiansen, C.3
Johnston, C.C.4
Khaltaev, N.5
-
3
-
-
0026670254
-
Perspective. How many women have osteoporosis?
-
Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. Perspective. How many women have osteoporosis? J Bone Miner Res 1992;7:1005-10.
-
(1992)
J Bone Miner Res
, vol.7
, pp. 1005-1010
-
-
Melton L.J. III1
Chrischilles, E.A.2
Cooper, C.3
Lane, A.W.4
Riggs, B.L.5
-
4
-
-
0026732689
-
The prevention and treatment of osteoporosis
-
Riggs BL, Melton LJ III. The prevention and treatment of osteoporosis. N Engl J Med 1992;327:620-7.
-
(1992)
N Engl J Med
, vol.327
, pp. 620-627
-
-
Riggs, B.L.1
Melton L.J. III2
-
5
-
-
0028586042
-
Comparison of new biochemical markers of bone turnover in late-postmenopausal osteoporotic women in response to alendronate treatment
-
Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late-postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
-
(1994)
J Clin Endocrinol Metab
, vol.79
, pp. 1693-1700
-
-
Garnero, P.1
Shih, W.J.2
Gineyts, E.3
Karpf, D.B.4
Delmas, P.D.5
-
6
-
-
0027279616
-
Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties
-
Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 1993;53:283-8.
-
(1993)
Calcif Tissue Int
, vol.53
, pp. 283-288
-
-
Guy, J.A.1
Shea, M.2
Peter, C.P.3
Morrissey, R.4
Hayes, W.C.5
-
7
-
-
0029875341
-
Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae
-
Balena R, Markatos A, Seedor JG, et al. Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J. Pharmacol Exp Ther 1996;276:277-83.
-
(1996)
J. Pharmacol Exp Ther
, vol.276
, pp. 277-283
-
-
Balena, R.1
Markatos, A.2
Seedor, J.G.3
-
8
-
-
0027139913
-
The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhman primates
-
Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhman primates. J Clin Invest 1993;92:2577-86.
-
(1993)
J Clin Invest
, vol.92
, pp. 2577-2586
-
-
Balena, R.1
Toolan, B.C.2
Shea, M.3
-
9
-
-
0030868816
-
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis
-
Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
-
(1997)
J Clin Invest
, vol.100
, pp. 1475-1480
-
-
Chavassieux, P.M.1
Arlot, M.E.2
Reda, C.3
Wei, L.4
Yates, A.J.5
Meunier, P.J.6
-
10
-
-
0028851590
-
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
-
Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
-
(1995)
N Engl J Med
, vol.333
, pp. 1437-1443
-
-
Liberman, U.A.1
Weiss, S.R.2
Bröll, J.3
-
11
-
-
0027454352
-
Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
-
Garnero P, Delmas PD. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
-
(1993)
J Clin Endocrinol Metab
, vol.77
, pp. 1046-1053
-
-
Garnero, P.1
Delmas, P.D.2
-
12
-
-
0026676875
-
A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen crosslinked N-telopeptides in urine
-
Hanson DA, Weiss MAE, Bollen AM, Maslan SH, Singer FR, Eyre DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen crosslinked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
-
(1992)
J Bone Miner Res
, vol.7
, pp. 1251-1258
-
-
Hanson, D.A.1
Weiss, M.A.E.2
Bollen, A.M.3
Maslan, S.H.4
Singer, F.R.5
Eyre, D.R.6
-
13
-
-
0029116697
-
Alendronate treatment of the postmenopausal osteoporotic woman: Effect of multiple dosages on bone mass and bone remodeling
-
Chesnut CH III, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
-
(1995)
Am J Med
, vol.99
, pp. 144-152
-
-
Chesnut C.H. III1
McClung, M.R.2
Ensrud, K.E.3
-
14
-
-
0028846051
-
Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
-
Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
-
(1995)
Bone
, vol.17
, pp. 383-390
-
-
Adami, S.1
Passeri, M.2
Ortolani, S.3
-
15
-
-
0004851872
-
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
-
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
-
(1996)
Lancet
, vol.348
, pp. 1535-1541
-
-
Black, D.M.1
Cummings, S.R.2
Karpf, D.B.3
-
16
-
-
0031006598
-
Prevention of non-vertebral fractures by alendronate: A meta-analysis
-
Karpf DB, Shapiro DR, Seeman E, et al. Prevention of non-vertebral fractures by alendronate: a meta-analysis. JAMA 1997;277:1159-64.
-
(1997)
JAMA
, vol.277
, pp. 1159-1164
-
-
Karpf, D.B.1
Shapiro, D.R.2
Seeman, E.3
-
17
-
-
0025765521
-
Pre-existing fractures and bone mass predict vertebral fracture incidence in women
-
Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114:919-23.
-
(1991)
Ann Intern Med
, vol.114
, pp. 919-923
-
-
Ross, P.D.1
Davis, J.W.2
Epstein, R.S.3
Wasnich, R.D.4
-
18
-
-
0028262189
-
Risk of hip fracture in women with vertebral fracture
-
Kotowicz MA, Melton LJ III, Cooper C, Atkinson EJ, O'Fallon WM, Riggs BL. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 1994;9:599-605.
-
(1994)
J Bone Miner Res
, vol.9
, pp. 599-605
-
-
Kotowicz, M.A.1
Melton L.J. III2
Cooper, C.3
Atkinson, E.J.4
O'Fallon, W.M.5
Riggs, B.L.6
-
19
-
-
0026630460
-
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders
-
Talley NJ, Weaver AL, Zinsmeister AR, Melton LJ III. Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol 1992;136:165-77.
-
(1992)
Am J Epidemiol
, vol.136
, pp. 165-177
-
-
Talley, N.J.1
Weaver, A.L.2
Zinsmeister, A.R.3
Melton L.J. III4
-
20
-
-
0010496839
-
Esophagitis associated with the use of alendronate
-
de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
-
(1996)
N Engl J Med
, vol.335
, pp. 1016-1021
-
-
De Groen, P.C.1
Lubbe, D.F.2
Hirsch, L.J.3
|